Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...
MiNK Therapeutics announced a Phase 2 trial evaluating a novel iNKT cell therapy combination for advanced gastroesophageal cancer at ASCO GI. MiNK Therapeutics, Inc. announced that it will present ...
In terms of research and development, MiNK Therapeutics' ongoing gastric cancer trials have seen robust enrollment, with results expected to be presented at an upcoming medical conference.
The map is now available for a one-month trial run on the Beijing Platform for Common Geospatial Information Services. The Beijing English Map includes both digital and printed versions.
The map is now available for a one-month trial run on the Beijing Platform for Common Geospatial Information Services. The Beijing English Map includes both digital and printed versions. The digital ...
ISLAMABAD, Pakistan The Foreign Office of Pakistan has issued a forceful and unequivocal response to U.S. President Donald Trump's... WASHINGTON, D.C.: U.S. President Donald Trump has invited Indian ...
By Hurubie Meko Stephen K. Bannon’s trial on fraud charges will start in March, a week later than previously scheduled, and will include a high-profile lawyer after a judge granted Mr. Bannon ...
She has covered celebrity deaths, lawsuits, and the Hunter Biden gun trial. Erin joined Newsweek in 2024 from the New York Post and had previously worked at News Center Maine. She is a graduate of ...
Prince Harry's trial has suffered a second delay on its first day at the High Court. The Duke of Sussex and Labour MP Tom Watson's case against News Group Newspaper was scheduled to start at 10:30am ...
She has covered celebrity deaths, lawsuits, and the Hunter Biden gun trial. Erin joined Newsweek in 2024 from the New York Post and had previously worked at News Center Maine. She is a graduate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results